Triamcinolone Acetonide

Corticosteroid Glucocorticoid

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog PO 0.1-0.2 mg/kg q12h or q24h Duration: Varies; taper after response
Notes: Use lowest effective dose; alternate-day therapy may be considered for maintenance.
Dog IM 0.1-0.2 mg/kg q24h or as needed Duration: Short-term for acute conditions
Notes: For depot effect, use triamcinolone acetonide suspension.
Dog Intra-articular 2-10 mg per joint (depending on joint size) Single injection; may repeat after 3-4 weeks Duration: As needed
Notes: Strict aseptic technique; avoid repeated injections in the same joint.
Cat PO 0.1-0.2 mg/kg q12h or q24h Duration: Varies; taper after response
Notes: Use lowest effective dose; monitor for diabetes mellitus.
Cat IM 0.1-0.2 mg/kg q24h or as needed Duration: Short-term for acute conditions
Notes: For depot effect, use triamcinolone acetonide suspension.
Cat Intra-articular 1-4 mg per joint (depending on joint size) Single injection; may repeat after 3-4 weeks Duration: As needed
Notes: Strict aseptic technique; avoid repeated injections in the same joint.
Horse Intra-articular 6-18 mg per joint (depending on joint size) Single injection; may repeat after 3-4 weeks Duration: As needed
Notes: Strict aseptic technique; avoid repeated injections in the same joint.
Horse IM 0.02-0.1 mg/kg q24h or as needed Duration: Short-term for acute conditions
Notes: Use lowest effective dose; monitor for laminitis risk.
Cattle IM 0.02-0.1 mg/kg q24h or as needed Duration: Short-term for acute conditions
Notes: Use lowest effective dose; observe withdrawal times.
Cattle Intra-articular 6-12 mg per joint (depending on joint size) Single injection; may repeat after 3-4 weeks Duration: As needed
Notes: Off-label use; strict aseptic technique.
Small Ruminants IM 0.02-0.1 mg/kg q24h or as needed Duration: Short-term for acute conditions
Notes: Use lowest effective dose; observe withdrawal times.
Rabbit PO 0.1-0.2 mg/kg q12h or q24h Duration: Varies; taper after response
Notes: Use with caution; monitor for GI stasis.
Rabbit IM 0.1-0.2 mg/kg q24h or as needed Duration: Short-term for acute conditions
Notes: Use lowest effective dose.
Bird/Poultry PO 0.1-0.2 mg/kg q12h or q24h Duration: Varies; taper after response
Notes: Limited data; use with caution.
Bird/Poultry IM 0.1-0.2 mg/kg q24h or as needed Duration: Short-term for acute conditions
Notes: Limited data; use with caution.

Clinical Indications & Species Uses

General Indications
  • Anti-inflammatory and immunosuppressive therapy
  • Management of allergic and immune-mediated diseases
  • Local treatment of joint inflammation (intra-articular)
  • Adjunctive therapy in certain neoplastic conditions
Dog (Canine)
  • Inflammatory and allergic conditions (e.g., allergic dermatitis, atopy, pruritus)
  • Immune-mediated diseases (e.g., immune-mediated hemolytic anemia, thrombocytopenia, polyarthritis)
  • Neoplasia (as part of chemotherapy protocols, e.g., lymphoma)
  • Orthopedic conditions (intra-articular injection for osteoarthritis)
  • Ophthalmic conditions (topical or subconjunctival for uveitis, keratitis)
Cat (Feline)
  • Inflammatory and allergic conditions (e.g., allergic dermatitis, asthma, eosinophilic granuloma complex)
  • Immune-mediated diseases (e.g., immune-mediated hemolytic anemia, inflammatory bowel disease)
  • Neoplasia (as part of chemotherapy protocols, e.g., lymphoma)
  • Ophthalmic conditions (topical or subconjunctival)
Horse (Equine)
  • Intra-articular injection for joint inflammation (e.g., osteoarthritis, traumatic arthritis)
  • Inflammatory conditions (e.g., allergic dermatitis, urticaria)
  • Immune-mediated diseases (e.g., immune-mediated myositis, vasculitis)
  • Respiratory conditions (e.g., recurrent airway obstruction, inflammatory airway disease) - systemic or inhaled
Cattle (Bovine)
  • Inflammatory conditions (e.g., allergic reactions, respiratory disease complex)
  • Ketosis (adjunctive therapy)
  • Mastitis (adjunctive therapy)
  • Intra-articular injection for joint inflammation (off-label)
Small Ruminants (Sheep / Goat)
  • Inflammatory conditions (e.g., allergic reactions, respiratory disease)
  • Intra-articular injection for joint inflammation (off-label)
Rabbit & Small Mammals
  • Inflammatory conditions (e.g., allergic dermatitis, pododermatitis)
  • Immune-mediated diseases (e.g., encephalitozoonosis - adjunctive therapy)
Avian & Poultry
  • Inflammatory conditions (e.g., allergic reactions, dermatitis)
  • Immune-mediated diseases (e.g., autoimmune conditions) - limited use
Exotic & Other Species
  • Reptiles: Inflammatory conditions (e.g., abscesses, dermatitis) - limited use
  • Small mammals (e.g., ferrets, guinea pigs): Inflammatory conditions, immune-mediated diseases

Pharmacology & Mechanism of Action

Drug Class: Corticosteroid | Pharmacological Group: Glucocorticoid

Mechanism of Action: Triamcinolone acetonide is a synthetic fluorinated corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to translocation into the nucleus and modulation of gene transcription. This results in increased synthesis of lipocortin (which inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene production), and inhibition of pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-alpha). It also suppresses immune cell function, including macrophage and neutrophil activity, and reduces vascular permeability and inflammatory cell migration.

Pharmacodynamics: Triamcinolone acetonide has anti-inflammatory, immunosuppressive, and antipruritic effects. Its potency is approximately 5 times that of hydrocortisone and 1.3 times that of prednisolone. It has minimal mineralocorticoid activity, making it less likely to cause sodium and water retention compared to other corticosteroids. The duration of action is intermediate to long, especially when administered as a depot formulation (e.g., intra-articular or intralesional), providing prolonged local effects.

⚡ Pharmacokinetics Summary

Absorption: Triamcinolone acetonide is well absorbed after oral administration, but its systemic bioavailability is variable due to first-pass metabolism. After intramuscular or intra-articular injection, absorption is slow and prolonged, especially with the acetonide salt, which is poorly soluble. Topical absorption is minimal in healthy skin but can be enhanced in inflamed or damaged skin.
Distribution: It is widely distributed throughout the body, crossing the placenta and entering milk. It is highly bound to plasma proteins (approximately 68-80%), primarily corticosteroid-binding globulin and albumin. It distributes into synovial fluid, skin, and other tissues.
Metabolism: Triamcinolone acetonide is metabolized in the liver via reduction and conjugation, primarily by CYP3A4 enzymes. The acetonide group is slowly hydrolyzed to the active triamcinolone. Metabolites are inactive.
Excretion: Metabolites are excreted primarily in the urine, with a small amount in feces. The elimination half-life is approximately 2-5 hours for the parent drug, but the pharmacologic effect lasts much longer due to receptor binding and slow release from tissues.
Half-Life: Dog: ~1.5-2 hours (plasma); Cat: ~2-3 hours; Horse: ~1-2 hours; Cattle: ~2-3 hours
Bioavailability: Oral: ~50-70% (variable); IM: ~100% (slow release); Intra-articular: ~100% (local effect)
Protein Binding: 68-80%

Available Formulations & Strengths

Oral Tablet 4 mg (PO)
Injectable Suspension 40 mg/mL (IM, Intra-articular, Intralesional)
Topical Cream/Ointment 0.1% (Topical)
Ophthalmic Suspension 0.1% (Ophthalmic)

Contraindications & Clinical Warnings

Contraindications:
  • Systemic fungal infections
  • Known hypersensitivity to triamcinolone or other corticosteroids
  • Concurrent use of live vaccines (immunosuppression may impair immune response)
  • Gastrointestinal ulceration (may exacerbate)
  • Corneal ulceration (topical ophthalmic use)
  • Pregnancy (especially first trimester) unless benefits outweigh risks
  • Lactation (may cause adverse effects in nursing offspring)
Warnings & Clinical Precautions:
  • Use with caution in animals with diabetes mellitus, as corticosteroids may increase blood glucose.
  • Use with caution in animals with congestive heart failure, hypertension, or renal disease due to potential fluid retention (though mineralocorticoid activity is low).
  • Prolonged use may cause iatrogenic hyperadrenocorticism (Cushing's syndrome).
  • Abrupt withdrawal after prolonged therapy may lead to adrenal insufficiency; taper gradually.
  • In horses, systemic corticosteroids may increase the risk of laminitis; use with caution.
  • Intra-articular injections should be performed under strict aseptic conditions to avoid septic arthritis.
  • In food animals, observe withdrawal times; extra-label use requires veterinary oversight.
  • In cats, long-term use may increase the risk of diabetes mellitus and heart failure.
  • In rabbits and rodents, corticosteroids may cause immunosuppression and GI disturbances; use with caution.
  • In birds, corticosteroids may be immunosuppressive; use with caution.

Adverse Effects & Reactions

Common:

  • Increased thirst and urination (polydipsia/polyuria)
  • Increased appetite
  • Panting (in dogs)
  • Behavioral changes (e.g., lethargy, depression)
  • Gastrointestinal upset (vomiting, diarrhea)
  • Weight gain

Serious / Severe:

  • Iatrogenic hyperadrenocorticism (Cushing's syndrome) with prolonged use
  • Adrenal suppression and insufficiency upon withdrawal
  • Diabetes mellitus or worsening of pre-existing diabetes
  • Gastrointestinal ulceration and perforation
  • Pancreatitis
  • Laminitis in horses
  • Immunosuppression leading to opportunistic infections
  • Delayed wound healing
  • Hepatopathy (with high doses or prolonged use)

Rare:

  • Anaphylactic reactions
  • Seizures
  • Cardiac arrhythmias
  • Osteoporosis or pathological fractures (with long-term use)
  • Growth retardation in young animals
  • Behavioral changes (e.g., aggression, anxiety)

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Nonsteroidal anti-inflammatory drugs (NSAIDs) Increased risk of gastrointestinal ulceration and perforation. High
Insulin or oral hypoglycemic agents Corticosteroids may increase blood glucose, reducing the effectiveness of antidiabetic agents; dosage adjustments may be needed. Moderate
Phenobarbital or phenytoin Increased hepatic metabolism of corticosteroids, reducing their efficacy. Moderate
Ketoconazole or itraconazole May increase corticosteroid levels by inhibiting CYP3A4 metabolism, leading to increased effects and toxicity. Moderate
Cyclosporine Additive immunosuppression; may increase risk of infections. Moderate
Diuretics (e.g., furosemide) May enhance potassium depletion, leading to hypokalemia. Moderate
Vaccines (live) Immunosuppression may impair immune response and increase risk of vaccine-induced disease. High

Overdose & Toxicity Management

Signs of Toxicity:

  • Severe polydipsia and polyuria
  • Gastrointestinal ulceration and hemorrhage
  • Hyperglycemia and glycosuria
  • Electrolyte imbalances (hypokalemia, hypernatremia)
  • Hypertension
  • Behavioral changes (e.g., agitation, depression)
  • Immunosuppression and increased susceptibility to infections
  • In horses: laminitis

Emergency Treatment Protocol: Treatment is primarily supportive. There is no specific antidote. For acute overdose, induce vomiting (if oral and within 2 hours) and administer activated charcoal. Monitor vital signs, blood glucose, electrolytes, and fluid balance. Provide symptomatic care for gastrointestinal ulceration (e.g., gastroprotectants like omeprazole or sucralfate). In cases of severe hyperglycemia, insulin may be required. For chronic overdose, gradually taper the corticosteroid to avoid adrenal crisis. In severe cases, consider administration of exogenous ACTH to assess adrenal function. Supportive care may include IV fluids, electrolyte replacement, and antibiotics if infection occurs.

Food Animal Withdrawal Times

🥩 Meat: 30 days🥛 Milk: 7 days

Withdrawal times are estimates and may vary by formulation and country. For extra-label use, consult the Food Animal Residue Avoidance Databank (FARAD) or regulatory authorities. In cattle, withdrawal times for meat and milk are typically 30 days and 7 days, respectively, but may be longer for depot formulations. In poultry, withdrawal times for meat are not established; use is generally off-label.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light. Keep container tightly closed. Do not freeze. Store injectable suspension at room temperature; avoid excessive heat.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for use in dogs and cats for certain indications (e.g., injectable suspension for inflammatory conditions). Not approved for food animals in the US; extra-label use is common.

Extra-Label (Off-Label) Use: In the United States, extra-label use of triamcinolone acetonide in food animals is permitted under AMDUCA (Animal Medicinal Drug Use Clarification Act) with veterinary oversight, provided that withdrawal times are extended and residues are within tolerance. It is not approved for use in food animals in some countries; check local regulations. In horses, use is regulated under the Horseracing Integrity and Safety Act (HISA) and may be prohibited in competition.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Triamcinolone acetonide is a potent corticosteroid used for its anti-inflammatory and immunosuppressive properties. It is particularly useful for local administration (intra-articular, intralesional) due to its long duration of action. However, systemic use should be reserved for conditions where other corticosteroids are ineffective or when a longer duration of action is desired. In dogs and cats, it is often used for allergic and immune-mediated diseases, but long-term use requires careful monitoring for adverse effects such as diabetes mellitus and Cushing's syndrome. In horses, intra-articular injection is common for joint inflammation, but systemic use is limited due to the risk of laminitis. In food animals, use is extra-label and requires strict adherence to withdrawal times. Always use the lowest effective dose for the shortest duration possible, and taper the dose when discontinuing therapy to avoid adrenal insufficiency. Monitor patients for signs of infection, hyperglycemia, and gastrointestinal issues. For topical use, avoid application to large areas of damaged skin to minimize systemic absorption. In ophthalmic use, contraindicated in corneal ulcers. Client education is essential to ensure compliance and recognize adverse effects early.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)